Invention Grant
- Patent Title: Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
-
Application No.: US15843160Application Date: 2017-12-15
-
Publication No.: US10344063B2Publication Date: 2019-07-09
- Inventor: Lai-Xi Wang , Wei Huang
- Applicant: UNIVERSITY OF MARYLAND, BALTIMORE
- Applicant Address: US MD Baltimore
- Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
- Current Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
- Current Assignee Address: US MD Baltimore
- Agency: Olive Law Group, PLLC
- Agent Tristan A. Fuierer; Marianne Fuierer
- Main IPC: C07K14/47
- IPC: C07K14/47 ; C07K16/28 ; C12N9/24 ; A61K47/68 ; C07K16/00 ; C07K16/18 ; C12N1/20 ; C12P21/00 ; A61P31/18 ; A61P35/00 ; C12R1/46
Abstract:
The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.
Public/Granted literature
- US20180186847A1 CHEMOENZYMATIC GLYCOENGINEERING OF ANTIBODIES AND FC FRAGMENTS THEREOF Public/Granted day:2018-07-05
Information query
